MEREO BIOPHARMA GROUP PLC
Income Statement
| Line Item | Jun 2026 | Sep 2025 | Jun 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $500.0K | $0 | $0 | $0 | $0 | $1.0M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $1.8M | $4.3M | $5.4M | $8.8M | $3.2M | $4.9M | $4.0M | $4.8M |
| SG&A Expense | $5.2M | $6.0M | $5.5M | $6.5M | $6.2M | $7.9M | $5.9M | $3.6M |
| Operating Income | $-7.0M | $-10.0M | $-10.5M | $-15.3M | $-9.4M | $-12.8M | $-9.9M | $-7.1M |
| Operating Margin | — | — | -2,099.8% | — | — | — | — | -712.8% |
| Interest Expense | $16.0K | $28.0K | $24.0K | $376.0K | $353.0K | $331.0K | $310.0K | $352.0K |
| Pretax Income | $-7.0M | $-7.0M | $-14.6M | $-7.0M | $-15.0M | $-12.3M | $-9.0M | $-9.6M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $-532.0K |
| Net Income | $-7.0M | $-7.0M | $-14.6M | $-7.0M | $-15.0M | $-12.3M | $-9.0M | $-9.1M |
| Net Margin | — | — | -2,923.2% | — | — | — | — | -910.8% |
| EPS (Basic) | $-0.01 | $-0.01 | $-0.02 | $-0.01 | $-0.02 | $-0.02 | $-0.01 | $-0.01 |
| EPS (Diluted) | $-0.01 | $-0.01 | $-0.02 | $-0.01 | $-0.02 | $-0.02 | $-0.01 | $-0.01 |
| Shares Outstanding (Basic) | 803.6M | 799.9M | 799.4M | 739.6M | 770.1M | 770.1M | 700.3M | 659.5M |
| Shares Outstanding (Diluted) | 803.6M | 799.9M | 799.4M | 739.6M | 770.1M | 770.1M | 700.3M | 659.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |